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Bacterial immunostimulants — mechanism of action
and clinical application in respiratory diseases
Immunostymulujące preparaty pochodzenia bakteryjnego
— mechanizm działania i zastosowanie w chorobach układu oddechowego
Streszczenie
Odporność przeciw chorobom zakaźnym powstaje w wyniku procesów naturalnych (zakażenie) lub w wyniku interwencji
medycznej (szczepienia, podanie immunoglobulin, bakteryjnych preparatów immunostymulujących).
Wykazano, że immunostymulatory bakteryjne (ISs) zawierające lizaty bakterii (OM-85 BV, LW 50020) lub elementy ich
komórek (ekstrakt rybosomalny) indukują zarówno niespecyficzną, jak i swoistą (komórkową, humoralną) odpowiedź immu-
nologiczną organizmu. Dwoistość ich aktywności immunomodulacyjnej naśladuje lub w pewnym stopniu powtarza odpo-
wiedź immunologiczną rozwijającą się po wniknięciu patogenu do organizmu człowieka, która początkowo jest nieswoista
i stopniowo nabywa cech odpowiedzi swoistej. Jednak kliniczna skuteczność ISs w zapobieganiu infekcjom dróg oddecho-
wych (RTI) jest wciąż dyskutowana. W niniejszej pracy omówiono mechanizm działania immunomodulatorów i przeanalizo-
wano wyniki dostępnych danych klinicznych u dzieci i dorosłych.
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Abstract
Immunity towards bacteria might be achieved as a result of natural processes following infection, or as a consequence of
medical intervention including vaccination, administration of immunoglobulins or therapy with immunostimulants derived
from bacteria.
Bacterial immunostimulants (ISs) containing bacterial lysate (OM-85 BV, LW 50020) or components of bacterial cells
(ribosomal extracts) were shown to induce a non-specific response (i.e. intensification of phagocytosis) but also to orches-
trate both cellular (B, T cell stimulation) and humoral responses (antibodies and proinflammatory cytokines production).
Therefore, the duality of their immunomodulatory activity mimics or, to a certain extent, repeats the immune response
evoked by the intrusion of a pathogen into the human body, which is initially non-specific, but subsequently becomes
specific. However, their clinical efficacy in the prevention of respiratory tract infection (RTI) is still debated. This article
reviews their mechanism of action, as well as the available clinical data, discussing the pros and cons of their use in the
prevention of RITs in children and adults.
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Introduction
Immunity towards bacteria might be achieved as
a result of natural processes following infection, or as
a consequence of medical intervention including vac-
cination, administration of immunoglobulins or the-
rapy with immunostimulants derived from bacteria.
While vaccination initiates a response similar
to natural contact with an antigen, i.e. activation
of immunocompetent cells, production of cytoki-
nes and specific antibodies, administration of pre-
formed immunoglobins provides a direct, though
passive and relatively short-lived, form of defen-
ce. Interestingly, bacterial immunomodulators
(IMs) that contain killed bacteria, their lysate or
components of bacterial cells were proved to in-
crease the efficiency of immune system response,
via both a specific as well as a non-specific effect
on the cellular and humoral mechanisms [1–3].
Thus, the duality of their immunomodulatory ac-
tivity mimics or, to certain extent, repeats the im-
mune response evoked by the intrusion of a patho-
gen into the human body, which is initially non-
-specific, but subsequently becomes specific.
Since the 1970s, when the concept of the bac-
teria-derived immunomodulators appeared, vario-
us products were developed and accepted mostly
for the supplementary treatment of recurrent re-
spiratory tract infections. Here, we revisit the mode
of their action in the context of the most recent data
and hypotheses on the mechanism of antibacterial
innate and adaptative immune responses.
Mechanism of action
The main gateways for micro-organism pene-
tration into the human body are epithelial surfa-
ces and mucosa. This explains why over 50% of
lymphoid tissue is strategically located in this area,
as so-called MALT (Mucosal-Associated Lympho-
id Tissue). MALT consists of: NALT (Nasal-Asso-
ciated Lymphoid Tissue), BALT (Bronchus-Asso-
ciated Lymphoid Tissue), GALT (Gut-Associated
Lymphoid Tissue) and urogenital system lympho-
id tissue, covering therefore most of the internal
body surfaces accessible for microorganisms [4].
Consequently, bacterial immunomodulators
follow the route of naturally evoked immune re-
sponse in a way of being administered orally (not
parenterally, as typical vaccines). They are absor-
bed in the intestine, triggering GALT stimulation
and subsequently generating the immune respon-
se within mucosal tissue in other organs including
BALT [2, 5]. The key factors in this chain-like re-
action are reactive Peyer’s patches of GALT, re-
sponsible for the alien antigen identification and
subsequent generation of the adequate response.
It should be mentioned that 3 structurally and
functionally different regions have been distingu-
ished in the Peyer’s patches structure: lymph no-
dules — mostly formed by the cluster of B cells,
internodule areas — generally containing T cells
and dome-like structures consisting of M cells, and
follicle-associated epithelium — marked by the
extraordinarily porous basal membrane. The
M cells are characterized by the presence of micro-
folds, pocket-like structures where lymphocytes,
mostly T and B memory cells (so called M-cell as-
sociated T-, B-cells) rather than macrophages and
neutrophils, are located. It is now believed that the
most important function of M cells is the trapping
of micro-molecules from the intestinal lumen fol-
lowed by their transfer to the subepithelial region,
in which they are processed by mucosal membra-
ne macrophages or dendritic cells (DCs) and pre-
sented to the lymphocytes. As a result, antigen-
-specific T and B cells are generated in the Peyer’s
patches as well as a considerable number of lym-
phoblasts, mostly IgA+ precursors of the IgA-pro-
ducing plasmocytes. Subsequently, lymphocytes
and lymphoblasts are transported with the lymph
from Peyer’s patches into the mesenteric lymph
nodes to mature. From the lymph nodes, activated
lymphocytes get into the blood stream via the tho-
racic duct and finally return to all MALT-associa-
ted structures in different organs, e.g. airways [5].
Therefore, the protective effect of bacteria-deri-
ved immunomodulators is particularly related to me-
mory cells, both T and B, enabling quick and specific
cellular and humoral responses as a result. It is belie-
ved that antigen-defined induction of immunoglobu-
lin (Ig) synthesis, mostly A isotype (secretory IgA –
sIgA), is the most important protective activity aga-
inst respiratory tract infection, providing help in on-
going and future contact with the same antigen. Both
an increased number of IgA+ plasmocytes as well as
IgA in the upper and lower respiratory tract have been
observed. Observations concerning the corresponding
changes in the peripheral blood are conflicting.
The cellular-specific response is also modified
simultaneously to the humoral response. IMs in-
ducing interferon gamma (IFN-g) and interleukin-12
(IL-12) production by some immunocompetent
cells might allow preferential stimulation of the
Th1 response. Besides, some studies demonstrated
an increased ratio of CD4+/CD8+ cells in the local
airways following treatment with IMs.
As well as antigen-specific defensive mecha-
nisms, immunomodulators also evoke a non-spe-
cific response enhancing the activity of the main
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phagocytic cells constituting innate immunity in the
lungs: monocytes, alveolar macrophages and granu-
locytes. Innate or natural immunity is the principal
way for the effective elimination of bacterial organi-
sms that have reached bronchioles and alveoli. The
effectiveness of this first-line response is increased
by the immunomodulators by means of enhanced
expression of adhesion molecules on monocytes
(lymphocyte function-associated antigen-1 (LFA-1,
CD11a/CD18), Mac-1 (CD11b/CD18), intercellular
adhesion molecule-1 (ICAM-1)) and neutrophils
(Mac-1, ICAM-1) important for their transendothe-
lial migration from the blood stream into the respi-
ratory tissues. Similarly, the stimulation of alveolar
macrophages and granulocytes phagocyte activity
allows efficient annihilation of the foreign organisms
that reach distal airways [4, 6]. Mauel et al. demon-
strated that bacterial immunomodulators enhance
“respiratory burst” — superoxide and nitrite produc-
tion by alveolar macrophages, therefore increasing
their microbicidal and cytolytic activities. Likewise,
their stimulatory effect on the production of key pro-
inflammatory cytokines (tumour necrosis factor a
(TNF-a), IL-8, IL-6, monocyte chemotactic protein-1
(MCP-1)) has been demonstrated [7].
In addition to the effects listed above, it has been
suggested that bacterial immunomodulators might
induce a considerable positive effect on the antigen-
presenting cells (APCs) and DCs functional activity.
Accordingly, enhanced expression of CD83, CD86
and class II human leukocyte antigen (HLA) mole-
cules markers of DCs maturation has been observed
following IM application, while increase in IL-12
production demonstrated in DC cultures in vitro
might be important for preferential triggering of
a Th1-type response (fig. 1).
Bacterial immunomodulators
OM-85 BV (Broncho-Vaxom)
OM-85 BV preparation contains lysates of eight
bacterial pathogens (in equal parts), the most often
encountered microorganisms in respiratory tract in-
fections: Haemophilus influenzae, Streptococcus
pneumoniae, Klebsiella pneumoniae, Klebsiella oza-
enae, Staphylococcus aureus, Streptococcus pyogenes,
Streptococcus viridans, Neisseria catarrhalis [3, 8].
As a typical bacterial immunostimulator (IS),
OM-85 BV was proved to affect both innate immu-
nity influencing macrophages, neutrophils activi-
ty and proinflammatory cytokines production, as
well as acquired immune response regulated by lym-
phocytes and synthesis of immunoglobulins [3, 7].
Several in vitro studies demonstrated significant
up-regulation of the oxidative metabolism, super-
oxide anion and nitric oxide production, and rele-
ase by macrophages due to OM-85 BV administra-
tion. In vivo, OM-85 BV effectively boosted patho-
gen destruction by increasing macrophage activa-
tion (phagocytosis and antigen presentation) and
Figure 1. Mechanism of action of the oral immunostimulators [51]
Rycina 1. Mechanizm działania doustnego immunostymulatora [51]
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natural killer (NK) cell migration, activity and an-
tigen recognition. Moreover, OM-85 BV stimulated
the expression of proinflammatory cytokines in
macrophages and monocytic cells, mainly of IFN-g,
IL-2, IL-1, IL-6, IL-8 and TNF-a, therefore affecting
indirectly natural and acquired immunity by sti-
mulation of T and B lymphocytes, granulocyte
migration and macrophage phagocytic activity [3,
8–10]. OM-85BV was shown to increase expression
of adhesion molecules on circulating monocytes
and granulocytes — LFA-1, MAC-1, protein p150,
intercellular adhesion molecule-1 (ICAM-1) media-
ting T cells APC interaction and immune cell mi-
gration, resulting in their increased activity [8].
It should also be mentioned that in newborn
animals OM-85 BV encouraged preferential deve-
lopment of the Th1-type immunity characterized
by amplified IFN-g and decreased IL-4 production
[11]. Interestingly, it was also found to act as
a maturation-inducing factor for human DCs, as po-
tent as TNF-a [12]. In human studies, an increased
content of secretory IgA in bronchoalveolar lava-
ge fluid in chronic bronchitis patients and heal-
thy controls saliva as well as serum IgG, IgA and
IgM levels were observed upon OM-85 BV treat-
ment, reflecting up-regulation of specific immune
response towards bacterial pathogens included
into the lysate [13, 14].
LW 50020 (Luivac)
LW 50020 contains bacterial lysate of a sligh-
tly different profile, consisting of: Staphylococcus
aureus, Streptococcus mitis, Streptococcus pyoge-
nes, Streptococcus pneumoniae, Klebsiella pneumo-
niae, Moraxella (Branhamella) catarrhalis, Haemo-
philus influenzae.
LW 50020 has been demonstrated to conside-
rably stimulate lymphocytes proliferation as well
as T cell activity in the mesenteric lymph nodes
model [15, 16]. Accordingly, up-regulated local
production of IL-2 and IFN-g was observed in the
mesenteric lymph nodes and BALf from experi-
mental animals [15–17], while IL-5 and IL-6 secre-
tion was enhanced in cultured animal pulmonary
lymphocytes [18]. In healthy volunteers treated
with LW 50020, up-regulation of T lymphocytes
proliferative activity was noted, as well as incre-
ased relative numbers of CD4, CD8 and memory
cells (CD45RO+) in bronchial lamina propria. Mo-
reover, a raise in serum IL-1b, IL-6 and sICAM-1
levels was observed [19, 20].
Animal studies also demonstrated that oral
administration of LW 50020 resulted in plasmocy-
tes proliferation within Peyer’s patches and in the
BALT system, consequently leading to the incre-
ased production of specific IgA, mostly sIgA [21, 22].
An increased density and percentage of secondary
lustre lymphoid cells containing specific antibo-
dies producing cells in the tonsils of children tre-
ated with LW 50020 [23]. Accordingly, clinical
trials showed higher levels of specific IgA and sIgA
in the saliva of patients with recurrent respiratory
tract infections subjected to immunostimulation
with LW 50020, compared to the control group [24, 25].
The blocking of adhesion of bacteria to the nasal
mucosa epithelial cells as a result of specific anti-
body presence was proven [26].
 It has also been documented that the over-
expressed intrapulmonary response to Streptococ-
cus pneumoniae infection was reduced in animals
orally immunized with the LW 50020 bacterial
lysate, mainly by suppression of exaggerated PMN-
-elastase synthesis [17]. Simultaneously, enhance-
ment of neutrophils, alveolar macrophages and
peripheral blood cell phagocytic activity [27] as
well as intensification of their oxidative capacity
were observed as well [16, 28].
Ribosomal extract (Ribomunyl)
Ribosomal extract contains the immunogenic
cellular components, i.e. ribosomes of bacteria,
most often responsible for recurrent respiratory
tract infections: Klebsiella pneumoniae, Streptococ-
cus pneumoniae, Streptococcus pyogenes and Ha-
emophilus influenza, together with the proteogly-
cans from cell membrane of Klebsiella pneumoniae
strain [29, 30]. It has been suggested that strong
nonspecific immune response evoked by this par-
ticular extract in experimental studies is mostly
due to its unique content, particularly proteogly-
can A protein (KpOmpA) derived from K. pneumo-
niae cell membrane. Interestingly, KpOmpA has
been described as a potential toll-like Receptor-2
(TLR-2) inducer, acquiring, therefore, attributes
adjuvant in vaccination [29]. Moreover, it was de-
monstrated that, similarly to other immunomodu-
lators of bacterial origin, dynamic nonspecific re-
sponse in subjects treated with ribosomal extract
preparation depends on NK, lymphocyte, DCs and
phagocyte stimulation [31] and on induced poly-
clonal nonspecific lymphocytes activation. Impor-
tantly, non-specifically activated B and T cells also
engage in specific actions leading to up-regulated
antibody production by plasmocytes or their incre-
ased ability to recognize and respond to antigens
[32]. That goes along with the above-mentioned
ability to induce TLR-2 receptors but also up-re-
gulated expression of certain DCs surface mole-
cules (CD83, CD86, HLA II) that actively partici-
pate in antigen presentation. Ribosomal extracts
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have been also proven both in vitro and in vivo,
to boost IL-12 production by DCs that could trig-
ger Th type 1 (Th1) response [33, 34]. Their down-
-regulatory effect on the CD4+cell population in
atopic children has been also suggested [35]. Con-
secutively, mounting non-specific macrophage
stimulation with the intensification of phagocy-
tosis and increased production of pro-inflamma-
tory cytokines TNF-a, MCP-1, IL-6, IL-8 results in
intensive, more effective combined specific and
non-specific resistance to infection [36, 37].
Apart from the cellular mechanisms, riboso-
mal extract, as other bacterial preparations, evo-
kes specific immune response increasing antibo-
dy levels in peripheral blood as well as those pro-
duced by MALT — mainly of IgA isotype.
Clinical effects
Respiratory tract infections (RTIs) in adults
and children are one of the primary causes of mis-
sed school days and absenteeism from work, as
well as morbidity and mortality in children and
particular groups of adults, mostly with other chro-
nic co-morbidities of the respiratory and cardio-
vascular system.
Though the therapeutic use of ISs derived from
bacteria is common in some European countries, the
clinical efficacy of these medications in the preven-
tion of RTIs is still debated. Also, most acute RTIs have
a viral origin, and it is not entirely clear how a bacte-
rial immunostimulant might prevent these infections.
It is usually suggested that highly suscepti-
ble patients have at least some immune disturban-
ces. It has been shown that 57% of children with
recurrent RTIs (3 or more episodes a year during
at least 2 years) were deficient in one of the IgG
subclasses while 17% were IgA deficient [38]. Si-
milar data are available for the adult population
[39]. Besides, selective IgA deficiency is known to
be linked with frequent bacterial and viral respi-
ratory infections [1]. Hence, the protective effect
of bacterial immunostimulants is attributed to the
enhancement of non-specific immunity as well
general activation of the cellular and humoral re-
sponses, mostly increased secretory IgA levels.
The clinical usefulness of bacterial immuno-
modulators in preventing respiratory tract infections
has been evaluated in a variety of individuals.
Several controlled studies have demonstrated
their significant beneficial effect in children with
RTIs, both young (< 6 yrs) as well as school chil-
dren, although some groups published totally ne-
gative results concerning the preventive effect of
bacterial immunotherapy [41].
Generally, in most IS treated groups, the
number of acute upper RTI episodes was signi-
ficantly lower and their duration shorter. Inte-
restingly, some authors have observed that youn-
ger children and children with higher incidence
of acute RTIs benefited more than others. Accor-
dingly, Paupe et al. showed that in 116 children
aged 0.6–19 years treated for 90 days with
OM-85 BV, the number of upper RTIs diagnosed
over a 6-month period of observation was 39.5%
in comparison to 16.5% in a placebo treated gro-
up. These differences were even greater in the
subgroup of children aged 6 years and less (34%
vs. 3.5%) [40]. However, Schaad et al. did not ma-
nage to reproduce these data in younger subjects.
Instead, they demonstrated that in a group of
170 children aged 36–96 months treated with three con-
secutive courses of OM-85 BV, upper RTIs reduction
was significantly greater mainly in those with a hi-
story of frequent RTIs (reduction of up to 22% in
comparison to a placebo group vs. 16% in the who-
le studied group) [41]. Still, no differences were
observed in the number of lower RTIs and antibio-
tic treatment between evaluated subsets, while lo-
cal antiseptic, anti-inflammatory and mucolytic
products were significantly less frequently used by
the OM-85 BV treated patients. Additionally, the im-
munomodulatory effect of bacterial extracts was
prone to wear off gradually after cessation of treat-
ment, although Paupe et al. did not report any si-
gnificant deterioration during the 90 days of follow-
-up period [40]. Two other placebo-controlled,
double-blind studies demonstrated even greater re-
ductions in the frequency and duration of upper RTIs
in highly susceptible children (by 52% and 38%)
treated with IS. However, both should be very cau-
tiously interpreted as the recruited groups were pro-
ne to unusually frequent RTIs (5 episodes in 6 mon-
ths prior to inclusion) due to the highly polluted
environment (Mexico City) or to the social condi-
tions favouring microbial contamination (orphana-
ge) [42, 43]. It is highly possible that the immune
status of the evaluated subjects differed from the
normal population as well as the children evaluated
in other studies. Therefore, it is debatable to what
extent the mentioned results and conclusions
might be extrapolated into other populations.
Interestingly, Guiterrez et al. also observed
monthly differences in ISs effect (May-August >
September-December) and suggested that the best
preventive outcome might be expected 2 months
after the start of treatment [43].
While the effect of ISs in upper RTIs has been
analyzed in a considerable number of studies, their
preventive ability towards lower RTIs in children
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was not extensively evaluated. Most of the available
studies have been conducted in rather small groups
or in patients with mixed upper/lower RTIs with no
separately reported data for bronchitis. Consequen-
tly, most conclusions concerning lower RTIs are of
rather speculative character, even though confirming
the considerable protective effect (by 48%) of ribo-
somal extract in a group of 45 children with recur-
rent acute infections [29]. Importantly, the safety and
tolerance of evaluated bacterial ISs in all paediatric
trials were good and comparable to placebo.
In adults, ISs have also been extensively eva-
luated, although mostly in subjects with chronic
pathologies of the respiratory tract, both upper and
lower, mainly chronic bronchitis, chronic obstruc-
tive pulmonary disease (COPD), bronchoectasis and
chronic sinusitis. Meanwhile, the ISs effect on the
frequency of recurrent acute RTIs episodes in the
typical Caucasian population has been poorly ana-
lyzed. There has been only one quality (randomi-
zed and double-blinded) study with 86 industrial
workers treated with OM-85 BV for 10 days repe-
atedly in 6 consecutive months. Considerably lower
incidence and severity of RTIs has been demonstra-
ted, but with no effect on absenteeism at work [44].
In addition, in patients with upper RTIs, bac-
terial ISs have not been extensively evaluated. Ri-
bosomal extract administered for 6 months were
proven to diminish the cumulative number of re-
current acute upper RTIs episodes (–40%) starting
from the first month and continuing until the end
of the study [45]. Likewise, patients with chronic
purulent sinusitis benefited from 3 month treatment
with OM-85 BV by means of the number and seve-
rity of exacerbations [46]. As in paediatric trials, the
final conclusions concerning the clinical usefulness
of bacterial extracts in lower RTIs in adults are gre-
atly limited due to the rather low quality of trials.
It should be strongly emphasized that only
a minority of the studies conducted in adults is of high
quality. Steurer-Stay et al. systematically reviewed
71 manuscripts concerning ISs effectiveness in the
lower RTIs, of which 25 were excluded due to the
lack of randomization, primary and secondary end-
-points and duplicated data, while a further 33 did
not contain clinical data or included no COPD/bron-
chitis patients. Out of 13 studies included in the re-
view, only 1 trial received the highest global quali-
ty score of 6, while 2 trials scored 4 each, on the
basis of multi-component methodological quality
assessment. The median score was 2, proving the
poor general quality of the evaluated studies [47].
The PARI-IS study, which scored the best ra-
ting in the mentioned systematic review and was
conducted as a large double-blind placebo-control-
led randomized trail in mild to moderate COPD
patients, clearly suggested the beneficial effect of
the ISs on reduction of hospitalization rate due to
severe exacerbations, but not on the prevention of
severe respiratory events. Meanwhile, another lar-
ge trial of acceptable quality showed a significan-
tly lower likelihood of hospitalization [48]. A re-
duction in the average duration of exacerbation of
approximately 3 days, as well as an improvement
in symptoms as rated by patients and observers,
were also reported, although the pooled results
came from studies of limited methodological qua-
lity [14, 49, 50]. As in the paediatric studies, side
effects were as common in the treated group as in
controls.
Also, it should be clearly articulated that the
majority of available studies were conducted in
mild-to-moderate COPD/chronic bronchitis pa-
tients and apply to this category of subjects only.
ISs effectiveness in reducing exacerbations in se-
vere patients needs to be evaluated separately. Due
to the complex pathophysiology of severe COPD
and multi-system involvement (including the im-
mune system), the above-mentioned results can-
not be directly extrapolated from severe patients.
Additionally, nothing is known about possible
additive or synergistic effects with recommended
treatment strategies.
Conclusions
In conclusion, strong evidence of the benefi-
cial effects of bacterial extracts on the lower RTIs
is still missing. However, their favourable effect on
certain clinical aspects, such as severity of symp-
toms, seems to be reasonably documented. Obvio-
usly, more carefully designed studies are needed
to answer many questions concerning the clinical
usefulness of bacterial extracts.
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